An advisory committee to the FDA has recommended authorizing booster shots of the Pfizer-BioNTech coronavirus vaccine for those 65 or older or those at risk of severe cases of COVID-19. But the committee declined to approve boosters for the general population citing lack of compelling evidence.
Breaking News: In a second vote, an FDA panel recommended authorizing a Pfizer booster for those 65 or older or at high risk of Covid. Earlier, the panel voted against recommending that they be authorized for everyone 16 or older.https://t.co/9bbreFu2KH
— The New York Times (@nytimes) September 17, 2021
From the New York Times:
The votes came after a sharp debate in which many of the panel’s independent experts, including infectious disease doctors and statisticians, challenged whether the data justified extra shots for so much of the population when the vaccines appear to still offer robust protection against severe Covid-19 disease and hospitalization, at least in the United States.
“It’s unclear that everyone needs to be boosted, other than a subset of the population that clearly would be at high risk for serious disease,” said Dr. Michael G. Kurilla, a committee member and official at the National Institutes of Health.
The recommendation will be “fine-tuned” next week by a CDC committee which is said to be considering boosters for seniors, nursing home residents and front-line health care workers versus the general population.
Read the full report here.
JUST IN: Vaccine advisers to the FDA have voted unanimously to recommend emergency use authorization of a booster dose of Pfizer's vaccine six months after full vaccination in people 65 and older and those at high risk of severe Covid-19. https://t.co/qCpwovgU9V
— CNN (@CNN) September 17, 2021